Close
The Cancer Research Domain's activities are overseen by a Steering Group composed of researchers from across UCL.
Co-chairs | ||
| Name | Affiliations | Research/expertise |
| Professor Daniel Hochhauser | UCL Cancer Institute; UCLH BRC; CRUK Centre co-lead | Chemo-DNA interactions, GI cancer |
| Professor Alison Lloyd | MRC Laboratory for Molecular Cell Biology | Cell growth, tissue regeneration, nerve repair, tumour development |
| Professor Gary Royle | UCL Department of Medical Physics and Biomedical Engineering | Imaging and sensor systems, RTx and proton therapy, cellular imaging |
Members | ||
| Name | Affiliations | Research/expertise |
| Professor Giuseppe Battaglia | UCL Chemistry | Synthesis, drug/gene carriers and delivery, diagnostics |
| Professor Mark Emberton | Dean, UCL Faculty of Medical Sciences | Prostate cancer |
| Professor Tariq Enver | Director, UCL Cancer Institute | Leukaemia, single cell analysis, stem cells |
| Dr Sahra Gibbon | UCL Anthropology | BRCA genetics, risk, inequities, public health |
| Dr Darren Hargrave | UCL Great Ormond Street Institute of Child Health | Paediatric neuro-oncology |
| Professor Jonathan Ledermann | UCL Cancer Institute; Director, CRUK Cancer Trials Centre | Cancer Trials and Gynaecological Cancers |
| Professor Paula Lorgelly | UCL Department of Applied Health Research | Economics of cancer |
| Professor Nick Luscombe | UCL Department of Genetics, Evolution and Environment; Francis Crick Institute; eMedLab | Bioinformatics, gene expression |
| Professor Georgios Lyratzopoulos | UCL Institute of Epidemiology & Health | Cancer epidemiology, behavioural science and health |
| Professor Mark Lythgoe | UCL Division of Medicine; Director of the Centre for Advanced Biomedical Imaging | Advanced imaging and tracking |
| Professor Emma Morris | UCL Division of Infection & Immunity; BRC; AHSC | Immunotherapy, transduced T cells, WT1 |
| Professor Andrew Pomiankowski | UCL Department of Genetics, Evolution and Environment | Genetics, sexual reproduction, evolution |
| Dr Martin Pule | UCL Cancer Institute | Engineered immune cell therapy, CAR T, commercial |
| Professor Rosalind Raine | Head of UCL Department of Applied Health Research; Director of NIHR CLAHRC North Thames | Cancer services, risk factors, screening |
| Professor Charlie Swanton | UCL Cancer Institute; Francis Crick Institute; CRUK Chief Clinician | Lung, heterogeneity, evolution |
| Professor Henning Walczak | UCL Cancer Institute; CRUK Centre co-lead | Cell death, immunity, inflammation |